A H-MnO2 nanoplatform for tumor microenvironment remodeling and multimodal synergistic therapy in prostate cancer Authors: Heng Zhang, Deqi Jiang, Luyao Huang, Lixiao Zhen, Zhipeng Yan, Chao Zhang, Maokun Sun, Yunji Sun Published: 2026 ABSTRACT The efficacy of chemotherapeutic drugs is inherently dose-dependent, and their clinical application is often limited by systemic toxicity and poor tumor selectivity. Manganese dioxide (MnO2) nanomaterials have attracted considerable interest in nanomedicine due to their favorable biocompatibility, efficient cellular uptake, and capacity to remodel the tumor microenvironment (TME). Docetaxel (DTX) remains a first-line treatment for advanced prostate cancer; however, its considerable side effects restrict therapeutic outcomes. To enhance the efficacy of DTX while reducing its toxicity, we encapsulated DTX into hollow MnO2 nanoparticles pre-loaded with the photosensitizer IR825, constructing a multifunctional nanoplatform designated H-MnO2@IR825/DTX. This nanoplatform leverages the catalase-like activity of H-MnO2 to catalyze the decomposition of tumor-overexpressed H2O2 into O2, thereby alleviating hypoxia and providing an endogenous oxygen source for photodynamic therapy (PDT). Under near‑infrared (NIR) irradiation, H-MnO2@IR825/DTX generates both localized hyperthermia for photothermal therapy (PTT) and a burst of reactive oxygen species (ROS), which synergizes with the controlled release of DTX to achieve multimodal antitumor treatment. Mechanistically, the ROS burst not only activates the mitochondrial apoptosis pathway but also triggers pyroptosis via the NLRP3/Caspase-1/Gasdermin D (GSDMD) signaling axis, as validated by both in vitro and in vivo experiments. Meanwhile, the decomposition of MnO2 depletes glutathione (GSH) and generates Mn2+ for chemodynamic therapy (CDT), further amplifying oxidative stress. Collectively, H-MnO2@IR825/DTX integrates TME remodeling with PTT, PDT, CDT, and chemotherapy, eliciting potent synergistic antitumor effects against prostate cancer through ROS-dependent apoptosis and pyroptosis, while exhibiting low toxicity to normal cells. This rationally designed nanoplatform represents a promising strategy for effective and safe prostate cancer therapy.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-58396-z. Introduction The incidence rate and mortality rate of prostate cancer are increasing year by year, and it has become a worldwide men’s health problem. In China, the incidence rate of prostate cancer has risen to the 6th place in the incidence rate of malignant tumors in men, accounting for 2.1% of the deaths of malignant tumors in men, and more and more patients with prostate cancer have already progressed to the advanced stage of prostate cancer at the time of the initial diagnosis1–3. The 2019 edition of the National Comprehensive Cancer Network (NCCN) guidelines recommends ADT therapy in combination with docetaxel as a first-line standard of care for patients with metastatic prostate cancer treated for the first time and able to tolerate chemotherapy4. However, docetaxel chemotherapy regimen has the disadvantages of greater systemic toxicity and insufficient targeting5,6, while long-term application of chemotherapy can cause tumor cells to develop multidrug resistance, leading to a decrease in the efficacy of chemotherapy, and it is also an important factor that restricts the clinical application of oncology chemotherapy in the long term7,8. Selection of targeted drug carriers or optimization of drug delivery modes can achieve synergistic and toxicity-reducing effects and provide therapeutic efficiency of chemotherapeutic drugs9. Nanomaterials have been widely valued and explored due to their properties such as small size at the nanometer level and relatively large surface area, which can be coupled with different biomolecules or loaded with a variety of imaging agents and antitumor drugs10. The microenvironment of a tumor is mainly composed of many different proteins and cells, such as epithelial cells, stromal cells, and external stroma11,12. The tumor microenvironment has many characteristics compared to the normal physiological environment, such as higher permeability, insufficient oxygen, acidic environment, and abnormal blood vessel growth13,14. Nanomaterials, on the other hand, can take advantage of the abundant blood vessels in the tumor microenvironment to penetrate and reach the tumor tissue, and stay in the tumor tissue for a longer period of time without being rapidly metabolized due to their own high permeability and retention effect15. Strategies of optical therapy have received increasing attention due to their higher targeting and noninvasiveness, and optical therapies that utilize exogenous photosensitizers to enhance the therapeutic effect of light radiation have emerged, including photothermal therapy (PTT) and photodynamic therapy (PDT)16. Photodynamic therapy (PDT) is an emerging therapeutic technology that employs photosensitizing agents activated by specific-wavelength external light irradiation to generate cytotoxic reactive oxygen species (ROS)—primarily singlet oxygen (1O2)—through a series of photochemical and photobiological reactions, destroying the double-stranded structure of DNA and causing apoptosis17,18. The fundamental mechanism of PDT relies on light-activated photosensitizers that, upon excitation by irradiation, mediate the conversion of molecular oxygen in the tumor microenvironment into singlet oxygen (1O2), a highly reactive cytotoxic agent. The antitumor efficacy of PDT is predominantly attributed to the direct cytotoxicity of singlet oxygen and its modulation of the tumor microenvironment.The content of ROS in tumor cells is significantly higher than that in normal tissue cells. Tumor cells can down-regulate the production of ROS by overexpressing antioxidant enzymes such as glutathione, glutathione peroxidase, and superoxide dismutase to maintain ROS at a specific physiological level to sustain the survival and proliferation of tumor cells19. In contrast, therapeutic doses of ROS can inhibit tumor cell proliferation and invasion, and cause DNA damage and apoptosis in tumor cells20,21. Hydroxyl radical (· OH) generated in chemodynamic therapy is one of the reactive oxygen species (ROS), which has stronger oxidative damage ability than H2O2 or superoxide anion in reactive oxygen species22–24.Enhancing ROS-dependent death signaling by increasing oxidative damage in tumor cells can effectively inhibit tumor progression25,26. Elevated ROS levels not only lead to tumor cytotoxic injury but also reverse chemoresistance and increase the anticancer effect of chemotherapy27. It was found that MnO2 nanoparticles could play a chemokinetic role in inducing apoptosis of tumor cells by catalyzing the conversion of H2O2, which is highly concentrated in the tumor microenvironment, to highly toxic •OH via a Fenton-like reaction. At the same time, MnO2 reacts with H+ or GSH in tumor cells and breaks down into Mn2+ to reduce the GSH content in the cells that resist oxidative stress damage, which strengthens the anti-tumor efficacy28,29. Building upon this rationale, we engineered a hollow MnO2 (H-MnO2) nanocarrier to modulate the hypoxic TME. H-MnO2 possesses catalase-like activity, catalyzing the conversion of TME-overexpressed H2O2 into O2, thereby improving oxygen availability for ROS-generating therapies (PDT/CDT). Concurrently, DTX was passively targeted and loaded to enhance its bioavailability and therapeutic index. Furthermore, the photosensitizer IR825 was immobilized onto the H-MnO₂ surface. This nanoconstruct (H-MnO2@IR825/DTX) leverages the photothermal effect and ROS generation triggered by NIR irradiation of H-MnO2@IR825, synergizing with DTX chemotherapy for multimodal antitumor action combining tumor targeting, PTT, PDT, and chemotherapy. Experimental section Synthesis of H-MnO2 nanoparticles Silica nanospheres sSiO2 was first prepared by Stober method, and then the prepared sSiO2 sample (50 mg) was dispersed into ultrapure water (50 mL), and the sample was added to potassium permanganate solution (6 g dissolved in 200 mL ultrapure water). After completion of addition under ultrasonic conditions, the reaction was continued for 12 h, followed by centrifugation at 11000 rpm for 30 min to collect the precipitate, which was subsequently washed three times with distilled water to obtain SiO2@MnO2 nanoparticles. The samples were dissolved in aqueous Na2CO3 solution (2 mol/L), centrifuged at high speed and stirred at 60℃ for 12 hours to obtain H-MnO2. After washing with distilled water for three times, the samples were stored in DMSO and stored in the refrigerator at 4℃ until use. Synthesis of H-MnO2@IR825 The photosensitizer IR825 was loaded onto the surface of H-MnO2 nanoparticles, and 50mg IR825(Shanghai McLean Biochemical Technology Co., LTD.) was added to 10ml DMSO(Beijing Solaibao Technology Co., LTD.) by shaking until dissolved. 10mg H-MnO2 was weighed and added to the solution and stirred continuously for 24 h at room temperature (22-24℃) by magnetic force. After washing the mixture with deionized water, the mixture was centrifuged at 12000 rpm for 30min. After washing again with deionized water, the concentrated H-MnO2@IR825 nanosamples were added to DMSO and stored at 4℃ in the dark. Synthesis of H-MnO2@IR825/DTX The chemotherapy drug docetaxel DTX was embedded in hollow mesoporous H-MnO2@IR825 nanoparticles, and 15 mL (1mg/mL) H-MnO2@IR825 nanoparticles were first lyophilized and then added to 10 mL (0.5 mg/mL) DTX solution and sonicated for 5 min. The mixture was then shaken overnight at room temperature (22-24℃ ) in the dark, washed twice with deionized water, and centrifuged at 12000 rpm for 10 min. After that, the concentrated H-MnO2@IR825/DTX nanoparticles were diluted to 1mg/mL with deionized water and stored at 4 ℃in the dark. Material characterization Transmission electron microscopy (TEM) images were acquired using a JEM-2100F transmission electron microscope. Element mapping were performed to analyze the distribution of Mn, O and C. X-ray photoelectron spectroscopy (XPS) (Thermo Scientific K-Alpha, USA) analysis was performed using an X-ray photoelectron spectrometer. Fourier transform-infrared spectra were obtained using a Thermo ls50 instrument (Thermo Scientific, Inc., USA).Dynamic light scattering (DLS; Zetasizer Nano Z; Malvern Instruments, Malvern, UK) was used to record the hydrodynamic particle size distribution and zeta potential of the NPs. Oxygen generation properties of the nanoparticles To evaluate the oxygen generation capability of the H-MnO2 nanoparticles, a series of experiments were conducted. In the first setup, H-MnO2 solutions of varying concentrations (0, 100, and 200 ppm) were prepared in EP tubes, each containing 1 mL of the nanoparticle solution with a fixed hydrogen peroxide concentration of 200 µM. The mixture was transferred to a 50 mL centrifuge tube using a pipette gun, and place the tube in a water bath set at 37℃ and maintain a stable ambient temperature.The dissolved oxygen concentration was measured every minute for 240 minutes using a portable dissolved oxygen meter (WLDO-300, Shanghai Water Instrument Technology Co., Ltd.). The oxygen electrode probe was placed directly into the reaction system to monitor oxygen generation in real time. To further investigate the effect of hydrogen peroxide concentration on oxygen production, a second set of experiments was performed using a fixed H-MnO2 concentration of 200 ppm. EP tubes containing 1 mL of the nanoparticle solution were prepared, and hydrogen peroxide was added to achieve final concentrations of 200, 500, and 1000 µM. The oxygen generation performance was continuously monitored for 240 minutes following the same procedure. Evaluation of temperature elevation ability of H-MnO2@IR825/DTX The photothermal properties of the H-MnO2@IR825/DTX nanoparticles were systematically evaluated. To assess the concentration-dependent photothermal heating effect, 1 mL aliquots of nanoparticle solutions at concentrations of 0, 50, 100, and 200 ppm were placed in a 96-well plate. Each sample was irradiated with an 808 nm laser at a power density of 2 W/cm2, and temperature changes were recorded over 30 minutes using a thermographic camera (FOTRIC 220S). The effect of laser power density on photothermal performance was investigated using a fixed nanoparticle concentration of 200 ppm. Under identical conditions, samples were exposed to 808 nm laser irradiation at power densities of 1, 2, and 3 W/cm2, and temperature variations were monitored over 30 minutes. Photothermal stability was examined by subjecting 1 mL of the nanoparticle solution (200 ppm) to six cycles of laser irradiation (808 nm, 2 W/cm2) with alternating 5-minute on/off intervals. Temperature changes were recorded throughout the 60-minute experiment. Photodynamic detection of H-MnO2@IR825/DTX nanoparticles To verify the photodynamic effect of the synthesized nanoparticles H-MnO2@IR825/DTX, the experimental results were evaluated by the detection probe SOSG singlet oxygen fluorescence probe, which is highly selective for 1O2. SOSG did not show any significant response to •OH and the superoxide radical •O2-, and the probe could emit a green fluorescence similar to that of fluorescein in the presence of singlet oxygen. 1 mL of H-MnO2@IR825/DTX nanosolution (200 ppm) was configured with hydrogen peroxide concentrations of 200, 500, and 1000 µM. The solution was added to a 96-well plate with a pipettes gun, and then it was placed under an 808 nm laser with a power density of 1 W/cm2 for 0, 1, 3, 6, 10, 15, 20, and 30 min. The Settings were: excitation wavelength 504 nm, emission wavelength 525 nm; The fluorescence intensity was scanned three times with a fluorescent microplate reader. The time was taken as the abscissa, and the fluorescence value A/A0 of the obtained nanoparticle solution was taken as the ordinate to obtain the singlet oxygen generation curve of the nanoparticle H-MnO2@IR825/DTX reaction with different concentrations of hydrogen peroxide. Detection of IR825 and DTX loading in H-MnO2@IR825/DTX nanoparticles and cumulative release of IR825 and DTX The ultraviolet-visible(UV-Vis) absorption spectra of H-MnO2@IR825 nanoparticles were acquired using a UV-Vis spectrophotometer. Standard solutions of IR825 were prepared at concentrations of 35, 40, 45, 50, and 62.5 μg/mL. Absorbance measurements were performed using the UV-Vis spectrophotometer to establish a calibration curve for IR825. Following nanoparticle synthesis, the absorbance of IR825 remaining in the supernatant (after centrifugation) was determined. This value was used to calculate the loading efficiency of IR825 onto the H-MnO2@IR825 nanoparticles. The UV absorption peak of DTX solution was measured by UV spectrophotometer (UV) at 282 nm. DTX solution with concentrations of 600, 700, 800, 900, 1000 ug/mL was prepared, and the standard curve of DTX solution was drawn. The drug loading of DTX was calculated by examining the OD value of the supernatant solution of the prepared H-MnO2@IR825/DTX sample. In the in vitro experiment, the acidic environment was simulated and buffer solutions with pH values of 6.0 and 7.5 were prepared. H-MnO2@IR825 was added to the dialysis bag, and then it was shaken at 200 revolutions per minute in 10 mM PBS at 37℃for 24 h. At fixed time points, 1 milliliter of dialysate was taken to measure its ultraviolet value, and the IR825 drug release rate curve was plotted. In the same way, the DTX drug release rate curve was detected and plotted. Cell culture Human prostate cancer cells PC3 were purchased from the Shanghai Qi Da Biotechnology Co.,Ltd. (Shanghai, China). PC3 cells were cultured in DMEM medium containing 10% Fetal Bovine Serum (FBS) and l % penicilysin mixture. Cultures were replaced every 1-2 days and subcultured every 3-5 days.Human prostate normal epithelial cells RWPE-1were purchased from the Wuhan Procell Biotechnology Co.,Ltd.(Wuhan, China). Evaluation of H-MnO2@IR825-DTX/FITC uptake by PC-3 cells The cellular uptake of nanoparticles was investigated using FITC-labeled H-MnO2@IR825/DTX. Notably, although IR825 itself is a fluorescent dye, its fluorescence properties can be significantly affected by aggregation within the nanoparticles and environmental factors such as pH, potentially compromising accurate intracellular tracking. Therefore, FITC was selected as an alternative fluorescent probe due to its stable fluorescence under physiological conditions, enabling reliable and reproducible visualization of nanoparticle internalization. Then 0.1 mg of FITC was weighed and dissolved in 0.1ml of DMSO solution. Then 0.1ml of FITC DMSO solution was added to 5mL of H-MnO2@IR825/DTX nano suspension, and sonicated at room temperature in the dark for 30 min to obtain H-MnO2@IR825-DTX/FITC. Excess FITC was removed with a dextran gel G-25 column, and H-MnO2@IR825-DTX/FITC was prepared and placed in a refrigerator at 4℃for later use. PC3 cells were seeded in 24-well culture plates at a density of 1×104cells per well in 500μL of medium. After culturing for 48 hours, when the cells reached approximately 80% confluence (approximately 2–3×104cells per well), the culture medium was removed and replaced with fresh medium containing the nanomedicine for treatment, After co-incubation for 1 hour, 3 hours, 6 hours, and 12 hours, the culture medium containing nanoparticles was removed and the cells were washed three times with PBS.The cells were further incubated with DAPI staining solution for 10min at room temperature, washed with PBS, and observed by fluorescence microscopy and photographed. Cytotoxicity studies in vitro To evaluate the safety profile of H-MnO2@IR825/DTX nanoparticles, the cytotoxicity of the nanomedicine was assessed using the CCK-8 assay in human normal prostate epithelial RWPE-1 cells. Briefly, RWPE-1 cells were seeded into 24-well culture plates at a density of 1×104 cells per well in 500 μL of culture medium. After culturing for 48 hours, when the cells reached approximately 80% confluence (approximately 2-3×104 cells per well), the culture medium was removed and replaced with fresh medium containing H-MnO2@IR825/DTX nanoparticles at concentrations of 0, 25, 50, 100, and 200 ppm. The cells were then incubated for 24 hours in a 37℃, 5% CO2 incubator. Subsequently, cell viability was measured using the CCK-8 kit and the calcein AM/PI double staining kit to evaluate the effect of different nanoparticle concentrations on normal cells. The killing effect of H-MnO2@IR825/DTX nanoparticles on tumor cells was evaluated using the same method.The procedure was as follows: PC3 cells were seeded in 24-well culture plates at a density of 1×104cells per well in 500μL of medium. After culturing for 48 hours, when the cells reached approximately 80% confluence (approximately 2-3×104cells per well), the culture medium was removed and replaced with fresh medium containing the nanomedicine for treatment.The cells were divided into 7 groups: group 1: PBS(control); Group 2: H-MnO2@IR825 group; Group 3: DTX group; Group 4: H-MnO2@IR825/DTX; Group 5: PBS+laser (control); Group 6: H-MnO2@IR825+laser; Group 7: H-MnO2@IR825/DTX+laser. After the cells were incubated with the nanomedicine in a 37℃, 5% CO2 incubator for 24 hours, the groups requiring laser irradiation were exposed to a power density of 2 W/cm2 for 10 min. CCK-8 kit was used to detect the cell viability to verify the anti-tumor effect of each treatment group in vitro. Apoptosis of PC3 cells was quantitatively evaluated using the PI/Annexin V apoptosis detection kit (BD Biosciences, Co., Ltd). After removing the original medium, the cells were incubated at 37℃ for 24 hours. Cells in the laser irradiation groups were exposed to an 808 nm laser at a power density of 2 W/cm2 for 10 minutes, and apoptosis was subsequently analyzed by flow cytometry. The Calcein AM/PI double staining kit was used to evaluate the effect of the nanoparticles on PC3 cells under laser irradiation and to analyze the in vitro anti-tumor effects of photodynamic therapy (PDT), photothermal therapy (PTT), and chemotherapy. Briefly, 1×104 PC3 cells were seeded into each well of a 24-well culture plate. When the cells reached approximately 80% confluence, the culture medium was replaced with medium containing the nanomedicine. The cells were divided into seven experimental groups. After incubation with the nanomedicine for 24 hours in a 37℃, 5% CO2 incubator, the groups requiring laser irradiation were exposed to a power density of 2 W/cm2 for 10 minutes. Finally, the cells were stained with the Calcein AM/PI double staining kit for 30 minutes and then observed and photographed under a fluorescence microscope. Reactive oxygen species production in PC3 cells The ability of H-MnO2@IR825/DTX nanoparticles to generate reactive oxygen species (ROS) in PC3 cells was evaluated using a ROS detection kit (Meilun Biochemical Technology Co., Ltd.), which is based on the fluorescent dye DCFH-DA for measuring intracellular ROS levels. Briefly, 1×104PC3 cells were seeded into each well of a 24-well culture plate containing 500 μL of culture medium and incubated for 24 hours. When the cells reached approximately 80% confluence, the culture medium was removed and replaced with fresh medium containing the nanomedicine. The cells were divided into seven groups: Group 1: PBS (control); Group 2: H-MnO2@IR825; Group 3: DTX; Group 4: H-MnO2@IR825/DTX; Group 5: PBS + laser (control); Group 6: H-MnO2@IR825 + laser; Group 7: H-MnO2@IR825/DTX + laser. After incubation with the nanomedicine for 12 hours in a 37℃, 5% CO2 incubator, the groups requiring laser irradiation were exposed to a power density of 2 W/cm2 for 10 minutes. ROS production in PC3 cells from each group was then observed under a fluorescence microscope. Western blotting Verification shows that the ROS produced by H-MnO2@IR825/DTX can lead to the death of PC3 cells through the pyroptosis pathway.The cells were divided into seven groups: Group 1: PBS(control); Group 2: H-MnO2@IR825; Group 3: H-MnO2@IR825+laser; Group 4: H-MnO2@IR825/DTX+laser; Group 5: H-MnO2@IR825+NAC (control); Group 6: H-MnO2@IR825/DTX +NAC; Group 7: H-MnO2@IR825/DTX+NAC+laser.After the cells in groups 5-7 adhered to the culture dish, the old culture medium was removed and replaced with fresh medium containing 10 mM N-acetyl-L-cysteine (NAC), and the treatment was carried out for 4 hours. After incubation with the nanomedicine for 12 hours in a 37℃, 5% CO2 incubator, the groups requiring laser irradiation were exposed to a power density of 2 W/cm2 for 10 minutes. Proteins were extracted from the cells lysates and supernatants. The concentration of proteins was measured by the BCA protein assay kit. The quantified proteins were separated by SDS-PAGE and then transferred onto the PVDF membrane. The membrane was blocked with 5% non-fat dry milk for 1 h, then incubated with primary antibody (1:1000 dilutions) overnight. The next day, the blot was visualized with HRP-conjugated secondary antibodies (1:5000 dilutions). All proteins were visualized with a western blotting substrate.Actin was used as the loading control.All Western blot images were captured and processed in accordance with the journal’s digital image integrity policy. Full-length blots with visible membrane edges are provided in the Supplementary Information. Establishment of animal tumor models Animal experiments were approved by the Ethical Committee of Shandong Provincial Third Hospital (No. DWKYLL-2024004) and performed in accordance with ARRIVE guidelines. BALB/c nude mice (4–6 weeks old, body weight approximately 20 g) were purchased from Jiangsu Huachuang Xino Medical Technology Co., Ltd. and housed in the Animal Experiment Center of the Third Hospital of Shandong Province under specific pathogen‑free conditions. The PC3 prostate cancer xenograft model was established by subcutaneous injection. PC3 cells were harvested, resuspended in precooled PBS at a concentration of 1×105 cells per 200 μL, and inoculated into the right axillary region of each nude mouse. Sample size calculation: Assuming a large effect size (Cohen’s d = 1.2), a significance level of α = 0.05, and a statistical power of 80% (1-β = 0.80), a minimum of 5 mice per group was required. To account for potential dropouts, we included 6 mice per group (n = 6). Randomization: When the tumor volume reached approximately 150 mm3, the tumor‑bearing mice were randomly assigned to seven experimental groups (n = 6 per group) using a computer‑generated random number sequence. The groups were as follows: Group 1: PBS (control); Group 2: H-MnO2@IR825; Group 3: DTX (free docetaxel); Group 4: H-MnO2@IR825/DTX; Group 5: PBS + laser (control); Group 6: H-MnO2@IR825 + laser; Group 7: H-MnO2@IR825/DTX + laser. All treatments were administered via tail vein injection. For groups requiring laser irradiation (Groups 5–7), irradiation was performed 24 hours after injection as described in Section "Establishment of animal tumor models". Tumor volume analysis in nude mice Twenty-four hours after the injection of nanomedicine into the tail vein, the laser irradiation group received 808nm wavelength laser irradiation for 10min at a power of 2W/cm2 for 14 days at an interval of 1 day. For the size of the tumor in nude mice, the long diameter (A) and short diameter (B) of the tumor bearing mice were measured every other day with a vernier caliper, and the tumor volume was calculated according to the formula V=A×B2/2. Biological distribution of H-MnO2@IR825/DTX nanoparticles First, H-MnO2@IR825/DTX solution was dispersed in PBS (1 mg/mL), then DiR solution was added, and magnetic stirring was performed (dark, 25℃, 6 h). Free DiR was removed by centrifugation (12,000 rpm, 15 min) and washed three times with PBS to obtain H-MnO2@IR825/DiR. When the tumor volume reached 150 mm3, two tumor-bearing nude mice were injected with 100 μL DiR and 100 μL MnO2@IR825/DTX/DiR, respectively, through the tail vein.According to the detection time point, the whole animal imaging system (LVIS Luwoma Series III, USA) was used to detect the fluorescence intensity. Detection by infrared thermography of H-MnO2@IR825/DTX in vivo The laser irradiation group was irradiated with 808nm wavelength laser at 2W/cm2 for 10min at 24h after injection of nanomedicine. One nude mouse in group 5, 6 and 7 was anesthetized by inhalation of isoflurane. During the process of laser irradiation, the temperature of the tumor site was monitored and recorded by infrared thermal imaging. Evaluation of histology The laser irradiation group was irradiated with 808nm wavelength laser at 2W/cm2 for 10min at 24h after injection of nanomedicine. One nude mouse in each group was anesthetized by inhalation, and the tumor was removed after death. The tumor tissue was immediately preserved in liquid nitrogen, and the difference in ROS production in the tumor was detected by frozen section. At the experimental endpoint, mice were deeply anesthetized using a high concentration of isoflurane (5%) in an induction chamber until the loss of consciousness and cessation of reflexes. Following confirmation of deep anesthesia, cervical dislocation was promptly performed to ensure death.This method complies with the euthanasia guidelines of the American Veterinary Medical Association (AVMA) and makes every effort to minimize the animals’ suffering. The removed tumors were subjected to a series of histological assessments, including hematoxylin-eosin (HE) staining for morphological changes of tumor cells, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining for apoptosis, and PCNA staining for proliferation. Detection of Hif-1ɑ expression difference in living animal tumors, the expression level of Hif-1ɑ is closely related to the invasion of tumors, detection of its expression difference is of great significance for evaluating the therapeutic effect and prognosis of tumors. To investigate whether the ROS burst induced by multimodal therapy triggers pyroptosis in prostate cancer cells, the expression levels of key pyroptosis-associated markers were assessed. Pyroptosis is a pro-inflammatory form of programmed cell death typically initiated by activation of the NLRP3 inflammasome and subsequent cleavage of Gasdermin D (GSDMD). Immunohistochemical (IHC) staining was performed on tumor tissue sections to detect the expression of NLRP3, Caspase-1, and GSDMD. Additionally, western blot analysis was conducted to quantify the protein levels of NLRP3, Caspase-1, GSDMD, and interleukin-1β (IL-1β) in tumor tissues from nude mice of each experimental group. Actin was used as the loading control. Biotoxicity testing of materials in vivo At the experimental endpoint, the liver, kidneys, heart, and lungs were taken for HE testing to investigate whether the nanoparticles used in the experiment were biologically toxic to nude mice. Statistical analysis Statistical analysis was performed using SPSS 20 software. Significant differences were determined using one-way analysis of variance (ANOVA) and Student’s t-test. A * denotes a p-value of < 0.05(significant result), ** denotes a p-value of < 0.01 (very significant),and *** denotes a p-value of < 0.001 (highly significant). Results and discussion Synthesis and characterization of H-MnO2@IR825/DTX TEM revealed that the prepared H-MnO2 nanoparticles exhibited a spherical morphology with uniform size (approximately 100 nm, Figure S1). The morphology of H-MnO2 nanoparticles did not change significantly after the loading of IR825 and DTX on the surface of H-MnO2 nanoparticles, indicating that the adsorption of drugs did not affect the structural stability of H-MnO2 nanoparticles (Fig. 1A and 1B).The composition and purity of the prepared nanoparticles were determined by qualitative and quantitative elemental analysis using energy dispersive spectroscopy (EDS) (Fig. 1C). Through EDS analysis, it was found that the prepared H-MnO2@IR825/DTX nanoparticles were mainly composed of Mn, C and O elements, and the proportion of Mn element was about 10.85%, while the proportion of C element and O element was about 78.35% and 10.22%, respectively (Fig. 1C, 1D and 1E). No doping of other metal elements was detected in the H-MnO2@IR825/DTX nanoparticle samples (Fig. 1F).Fig. 1Structural and physicochemical properties of the prepared H-MnO2@IR825/DTX nanocomplex.(A) TEM images of H-MnO2@IR825/DTX nanoparticles. (B) HAADF-STEM images of H-MnO2@IR825/DTX nanoparticles.(C-F) H-MnO2@IR825/DTX nanoparticles were mainly composed of Mn, C and O elements. (G-H) XPS of the H-MnO2@IR825/DTX nanoparticles. (I) Fourier transform-infrared spectra of the H-MnO2 and H-MnO2@IR825-DTX nanoparticles. (J) Zeta potential of the nanoparticles. (K) Particle size distribution of the nanoparticles.(L) The UV spectra of the nanoparticles. Structural and physicochemical properties of the prepared H-MnO2@IR825/DTX nanocomplex.(A) TEM images of H-MnO2@IR825/DTX nanoparticles. (B) HAADF-STEM images of H-MnO2@IR825/DTX nanoparticles.(C-F) H-MnO2@IR825/DTX nanoparticles were mainly composed of Mn, C and O elements. (G-H) XPS of the H-MnO2@IR825/DTX nanoparticles. (I) Fourier transform-infrared spectra of the H-MnO2 and H-MnO2@IR825-DTX nanoparticles. (J) Zeta potential of the nanoparticles. (K) Particle size distribution of the nanoparticles.(L) The UV spectra of the nanoparticles. The samples of H-MnO2@IR825/DTX nanoparticles were analyzed by X-ray energy spectrometer. By XPS spectroscopy, two significant peaks at 642.2 eV and 653.2 eV binding energies were identified, which correspond to the Mn2p 3/2 and Mn 2p1/2 signals of Mn2+ ions, respectively (Fig. 1G and 1H). Consistent with the XPS results of H-MnO2, the structure of H-MnO2 did not change after drug loading. The infrared spectrum analysis of H-MnO2@IR825/DTX nanoparticles using infrared spectroscopy can explore the molecular structure characteristics of H-MnO2@IR825/DTX and the vibration mode of its chemical bonds in detail. The spectral band of H-MnO2 loaded with IR825 and DTX overlaps with that of H-MnO2, and the results show that the structure of H-MnO2 is not changed after loading drugs (Fig. 1I).The Zeta potential of H-MnO2@IR825/DTX sample was measured by nanoparticle size potential analyzer. The results showed that the Zeta potential value of the sample was about -27.1 mV, while the Zeta potential value of H-MnO2 was about -32.6 mV, which proved that DTX was successfully loaded on the prepared H-MnO2 nanoparticles (Fig. 1J).Dynamic light scattering (DLS) analysis revealed the hydrodynamic diameters and polydispersity index (PDI) of the nanoparticles: H-MnO2 exhibited a size of 112.4±8.6 nm (PDI = 0.156); H-MnO2@IR825 showed a size of 156.3±10.2 nm (PDI = 0.182); and H-MnO2@IR825/DTX had a size of 198.7±12.4 nm (PDI = 0.208) (Fig. 1K). The nanoparticles were detected by ultraviolet spectrophotometer, and the results showed that DTX was successfully loaded into the nanoparticles, and the drug release rate was detected later (Fig. 1L). Based on the above results, it was confirmed that we successfully loaded IR825 and DTX on H-MnO2. Oxygen generation properties of the nanoparticles The oxygen generation capacity of H-MnO2 nanomaterials was evaluated in the presence of H2O2 using a portable dissolved oxygen meter. When H2O2 was added to deionized water at a final concentration of 200 µM, a slight gradual increase in dissolved oxygen content was observed over time, attributable to the spontaneous decomposition of H2O2 at 37℃. However, upon introduction of H-MnO2 nanoparticles, the dissolved oxygen level rose markedly and rapidly. This oxygen production exhibited a clear dependence on the concentration of H-MnO2, with higher nanoparticle concentrations leading to faster rates of oxygen release. Furthermore, when varying concentrations of H2O2 were introduced into a fixed concentration (200 ppm) of H-MnO2 solution, the dissolved oxygen content increased more rapidly at higher H2O2 concentrations (Fig. 2A). These results demonstrate that H-MnO₂ exhibits catalase-like activity, efficiently catalyzing the decomposition of H2O2 into O2 and thereby enhancing oxygen solubility in aqueous environments. Given that H2O2 is overexpressed in the tumor microenvironment compared to normal tissues, H-MnO2 can locally generate O2, supplying the necessary substrate for photodynamic therapy (PDT) and chemodynamic therapy (CDT).Fig. 2Evalution the performance characteristics of the nanoparticles. (A) Curves showing the oxygen concentration with respect to time in H-MnO2 solution containing H2O2. (B) Curves of the temperature change with respect to time for an H-MnO2@IR825/DTX solution subjected to laser irradiation. The concentration of H-MnO2@IR825/DTX was set to 0, 50, 100 and 200 ppm. (C) Verification of the photothermal stability of H-MnO2@IR825/DTX. (D) Infrared thermography images of different concentrations of H-MnO2@IR825/DTX solutions changing with time under laser irradiation.(E) Absorbance curves of singlet oxygen generated by the reaction of H-MnO2@IR825/DTX with H2O2 as a function of time under laser irradiation. Evalution the performance characteristics of the nanoparticles. (A) Curves showing the oxygen concentration with respect to time in H-MnO2 solution containing H2O2. (B) Curves of the temperature change with respect to time for an H-MnO2@IR825/DTX solution subjected to laser irradiation. The concentration of H-MnO2@IR825/DTX was set to 0, 50, 100 and 200 ppm. (C) Verification of the photothermal stability of H-MnO2@IR825/DTX. (D) Infrared thermography images of different concentrations of H-MnO2@IR825/DTX solutions changing with time under laser irradiation.(E) Absorbance curves of singlet oxygen generated by the reaction of H-MnO2@IR825/DTX with H2O2 as a function of time under laser irradiation. Photothermal characteristics of the nanoparticles The photothermal properties of the constructed nanoparticle H-MnO2@IR825/DTX were studied. Firstly, the photothermal heating of the solution with different concentrations of H-MnO2@IR825/DTX nanoparticles was detected. The solution concentration was set at 0, 50, 100, and 200ppm, and the solution temperature increased with time under 808 nm laser irradiation (Fig. 2B). When the concentration of H-MnO2@IR825/DTX nanoparticles was diluted to 200 ppm, the temperature of the reaction solution increased with the laser power density, and it became stable after a certain degree of increase, with good irradiation time and concentration dependence (Figure S3). The H-MnO2@IR825/DTX nanoparticles were subjected to six cycles of photothermal stability experiments with the laser density set at 2 W/cm2 for 10min each cycle (laser irradiation for 5min and laser off for 5min). The nanoparticle solution achieved a similar peak temperature in each cycle, indicating photothermal therapy stability (Fig. 2C). The FOTRIC thermograph was used to monitor the heating reaction of the nanoparticle solution, and the photos were taken at an interval of 2 minutes (Fig. 2D). It was observed that the high concentration of the nanoparticle solution showed an obvious heating reaction under laser irradiation. The results of photothermal performance experiments show that the synthesized H-MnO2@IR825/DTX nanoparticles are relatively stable photothermal conversion agents. Photodynamic characteristics of the nanoparticles The photodynamic properties of the synthesized nanoparticles H-MnO2@IR825/DTX were verified. The fluorescence intensity of the singlet oxygen fluorescent probe of SOSG was detected by fluorescent microplate reader. To evaluate the ability of H-MnO2@IR825/DTX nanoparticles to react with different concentrations of hydrogen peroxide (200, 500, 1000 µM) to form singlet oxygen under 808nm laser irradiation. The experimental results showed that the fluorescence intensity gradually increases with the increase of laser irradiation time, indicating that the H-MnO2@IR825/DTX nanoparticles could effectively generate singlet oxygen under laser irradiation. The results also showed that the generation of singlet oxygen was positively correlated with the concentration of hydrogen peroxide, and the generation of reactive oxygen species was also dependent on laser irradiation time (Fig. 2E). The experimental results provided strong evidence for its application in tumor therapy. Detection of IR825 and DTX loading in H-MnO2@IR825/DTX nanoparticles and cumulative release of IR825 and DTX The loading of IR825 onto H-MnO2 nanoparticles was quantified by UV-Vis spectrophotometry. A standard calibration curve was constructed using IR825 solutions at concentrations of 35, 40, 45, 50, and 62.5 µg/mL (Figure S4A). The supernatant of the H-MnO2@IR825 suspension exhibited an absorbance corresponding to a free IR825 concentration of 60.2 µg/mL. Based on the total supernatant volume (10 mL) and the initial IR825 input (3 mg), the loaded amount of IR825 was calculated to be 2.398 mg, giving an encapsulation efficiency of 79.93% (Figure S4B). These data demonstrate the efficient loading of IR825 onto the H-MnO2 nanocarrier. The UV absorption peak of DTX solution was measured by UV spectrophotometer (UV) at 282 nm. DTX solution with concentrations of 600, 700, 800, 900, 1000 ug/mL was prepared, and the standard curve of DTX solution was drawn (Figure S5A). By detecting the OD value of the supernatant of H-MnO2@IR825/DTX sample solution was 2.452, the DTX concentration in the supernatant was calculated as 152 ug/mL, the total volume of the prepared solution was 10 mL, the DTX content in the supernatant was 1.52mg, and the total amount of DTX added was 4 mg. The amount of modification was 2.48 mg (Figure S5B). Compared with the normal physiological environment, the tumor microenvironment has the characteristics of high permeability, insufficient oxygen, acidic environment, and abnormal blood vessel growth.The release data show that approximately 48.5 % of IR825 was released at pH 7.5 over 24 hours, while approximately 72.3 % was released at pH 6.0, indicating pH-responsive behavior. The corresponding results are presented as Figure S6A in the Supplementary Information. In the in vitro experiment, the acid environment was simulated, and the buffer of pH6.0 and pH7.5 was set.The results showed that the drug release rate of H-MnO2@IR825/DTX was higher in acidic environment (Figure S6 B). In vitro intracellular uptake studies FITC labeled H-MnO2@IR825/DTX nanoparticles were used to investigate the uptake of H-MnO2@IR825/DTX/FITC by PC3 cells. The uptake of nanoparticles by PC3 cells over time was observed under a fluorescence microscope. The PC3 cells were seeded in 24-well plates, and the drug medium containing H-MnO2@IR825/DTX/FITC was added after removing the original medium. The cells were observed by fluorescence microscope at 1h, 3h, 6h and 12h. The results showed that the cytoplasm showed obvious green fluorescence, indicating that the nanoparticles had entered the cytoplasm (Figure S7). The fluorescence intensity increased with time. The uptake of H-MnO2@IR825/DTX/FITC by PC3 cells showed a clear time-dependent manner. Cytotoxicity studies in vitro CCK-8 kit was used to detect the cell viability, and the relative cell viability under different treatment modes was detected to evaluate the therapeutic effect. After the cells added with the nanomedicine were incubated in a 37℃, 5%CO2 incubator for 12 h, the group requiring laser irradiation was irradiated at a power density of 2W/cm2 for 10 min. CCK-8 kit was used to detect the cell viability to verify the anti-tumor effect of each treatment group in vitro. The results showed that all the treatment groups except the control group could inhibit the proliferation of tumor cells, and H-MnO2@IR825/DTX had the strongest inhibitory effect on the proliferation of tumor cells under laser irradiation, and the therapeutic effect was better than that of the single treatment group, which confirmed that the synthesized nanoparticles had a synergistic therapeutic effect (Fig. 3A).Fig. 3Examination of the anti-tumor properties of the synthesized nanoparticles against prostate carcinoma PC3 cells. (A) Measurement of cell activity in each experimental group. (B) Quantitative analysis of cell apoptosis rates after Annexin V/PI staining of PC3 cells from each experimental group. (C) PC3 cell survival status analysis in each experimental group after CAM/PI staining. Examination of the anti-tumor properties of the synthesized nanoparticles against prostate carcinoma PC3 cells. (A) Measurement of cell activity in each experimental group. (B) Quantitative analysis of cell apoptosis rates after Annexin V/PI staining of PC3 cells from each experimental group. (C) PC3 cell survival status analysis in each experimental group after CAM/PI staining. To evaluate the safety profile of H-MnO2@IR825/DTX nanoparticles, the cytotoxicity of the nanomedicine was assessed using the CCK-8 assay in human normal prostate epithelial RWPE-1 cells. As the concentration of H-MnO2@IR825/DTX increased from 0 to 200 ppm, the viability of RWPE-1 cells showed a gradual decreasing trend, dropping from 100% to approximately 80%. Even at the highest tested concentration (200 ppm), the viability of normal cells remained above 80%, indicating that the nanomedicine exhibits low cytotoxicity toward human normal cells (Figure S8A and B). In comparison with the previously obtained data on PC3 prostate cancer cells, the nanoplatform displayed significantly higher cytotoxicity against cancer cells than against normal cells, demonstrating favorable selective toxicity and a wide therapeutic window. Apoptosis assay The apoptosis of PC3 cells was visualized using the PI/Annexin V apoptosis detection kit (BD Biosciences Co., Ltd.). In the control group, only 9.6% of the cells were apoptotic, indicating that the cells were in a good state of growth. The apoptosis rate of the drug treatment group was 14.3%, 20.2% and 23.3%, respectively. The apoptosis rate of the combined laser treatment group was significantly increased, and the apoptosis rate of the seventh group was as high as 30.4% after treatment, indicating that the synergistic treatment strategy in this study has enhanced the ability to kill tumors (Fig. 3B). The anti-tumor effect of each treatment group was evaluated by observing and evaluating the apoptosis of PC3 cells treated with different treatments by Calcein AM/PI double staining kit. The cells were stained with Calcein AM/PI double staining kit for 30 min and then observed and analyzed under a fluorescence microscope. The results showed that compared with the PBS treatment group, the tumor cells in the PBS treatment group were in a survival state, and the DTX and nano-drug treatment groups had varying degrees of cell death. The tumor cells in the H-MnO2@IR825/DTX nanodrug treatment group were in a typical apoptosis state after laser irradiation, and the apoptotic cells were significantly more than those in the other groups. The results showed that PTT and PDT combined with chemotherapy could synergistically enhance the anti-tumor effect and mediate tumor cell apoptosis (Fig. 3C). ROS production experiment based on PC3 cells The reactive oxygen species (ROS) production of H-MnO2@IR825/DTX nanoparticles in prostate cancer PC3 cells was evaluated by ROS detection kit. The PC3 cells were treated with DCFH-DA fluorescence staining, and the differences in ROS production between the different experimental groups were observed by fluorescence microscopy. The experimental results showed that the fluorescence intensity of the control group treated with PBS was the weakest, indicating that there was no significant intracellular ROS production in the absence of nanoparticles and laser irradiation stimulation. However, the H-MnO2@IR825 nanoparticles and H-MnO2@IR825/DTX nanoparticles produced reactive oxygen species in the cells without receiving laser irradiation, indicating that metal Mn had a Fenton-like reaction to produce reactive oxygen species in the tumor cells. The fluorescence intensity of H-MnO2@IR825 nanoparticles combined with laser irradiation was significantly enhanced, revealing that H-MnO2 can catalyze the production of oxygen from hydrogen peroxide in the tumor microenvironment, which provides sufficient raw materials for photodynamic therapy (Figure S9). Pyroptosis pathway activation induced by ROS burst To investigate whether the ROS burst generated by the multimodal nanoplatform triggers pyroptosis in prostate cancer cells, the expression levels of key pyroptosis‑related proteins were examined by western blotting.As shown in Fig. 4, the combination treatment with H-MnO2@IR825/DTX plus laser irradiation (Group 4) significantly upregulated the expression of NLRP3, cleaved Caspase-1 and the N-terminal fragment of Gasdermin D (GSDMD-N) compared to the control groups (Groups 1 and 2). In contrast, the addition of NAC (Groups 5-7) markedly suppressed the expression of these pyroptosis-related proteins, with Group 7 (NAC+ nanomedicine+laser) showing nearly baseline levels. These results confirm that the ROS burst induced by the multimodal therapy is essential for activating the NLRP3 inflammasome and subsequent pyroptotic cell death. Notably, H-MnO2@IR825 alone with laser irradiation (Group 3) also induced moderate upregulation of these markers, but the effect was less pronounced than that of the DTX‑loaded nanoplatform. Taken together, our findings demonstrate that H-MnO2@IR825/DTX combined with NIR irradiation promotes ROS-dependent pyroptosis via the NLRP3/Caspase-1/GSDMD signaling pathway, contributing to the potent antitumor efficacy against prostate cancer.Fig. 4The expression levels of key proteins related to pyroptosis were detected by western blotting. Group 1: PBS(control); Group 2: H-MnO2@IR825; Group 3: H-MnO2@IR825+laser; Group 4: H-MnO2@IR825/DTX+laser;Group 5: H-MnO2@IR825+ NAC (control); Group 6: H-MnO2@IR825/DTX +NAC; Group 7: H-MnO2@IR825/DTX+NAC+laser.All blots were not trimmed prior to antibody incubation; the band regions shown in the figure are from intact membranes, with trimming only removing areas without bands. The complete membrane images are shown in Supplementary Figure S10. The expression levels of key proteins related to pyroptosis were detected by western blotting. Group 1: PBS(control); Group 2: H-MnO2@IR825; Group 3: H-MnO2@IR825+laser; Group 4: H-MnO2@IR825/DTX+laser;Group 5: H-MnO2@IR825+ NAC (control); Group 6: H-MnO2@IR825/DTX +NAC; Group 7: H-MnO2@IR825/DTX+NAC+laser.All blots were not trimmed prior to antibody incubation; the band regions shown in the figure are from intact membranes, with trimming only removing areas without bands. The complete membrane images are shown in Supplementary Figure S10. In vivo anti-cancer efficacy of H-MnO2@IR825/DTX When the tumor size of PC3-bearing nude mice was about 150 mm3, the nude mice were randomly divided into 7 groups, 6 mice in each group, and 100uL of different drugs were injected into the tail vein: Group 1: PBS(control); Group 2: H-MnO2@IR825 group; Group 3: DTX group; Group 4: H-MnO2@IR825/DTX; Group 5: PBS+laser (control); Group 6: H-MnO2@IR825+laser; Group 7: H-MnO2@IR825/DTX+laser. Twenty-four hours after the injection of nanomedicine into the tail vein, the laser irradiation group received 808nm laser irradiation for 10min at a power of 2W/cm2 at an interval of one day.The animal experiment was conducted at Laboratory Animal Research Center of Shandong Provincial Third Hospital with approval by the Ethical Committee of Shandong Provincial Third Hospital. In the process of animal experimentation, strict adherence to the “3R” principles, which advocate Replacement, Reduction, and Refinement, should be strictly followed. Changes in the tumor volume in nude mice The tumor size of nude mice was recorded every other day. After 14 days, all nude mice were sacrificed after inhalation anesthesia(isoflurane), and the tumors were removed and measured with a vernier caliper.The average long axis of tumor was 13.32±1.73mm in Group1, 7.6±0.25mm in Group2, 5.96±0.5mm in Group3, 5.62±0.39mm in Group4, 13.2±0.98mm in Group5, 6.7±1.53mm in Group6 and 5.22±0.52mm in Group7.The nude mice in the PBS group(Group1) and the PBS combined with laser irradiation group(Group5) showed rapid tumor growth and significantly increased tumor volume. The tumor volume growth of nude mice injected with the nano-drug was inhibited, and the tumor volume of mice injected with H-MnO2@IR825/DTX combined with laser irradiation was significantly reduced after 14 days of treatment(Group7). The results showed that the combined treatment had the advantage of significantly reducing the tumor volume (Fig. 5A, 5B and S11). The comprehensive treatment mode based on photothermal therapy combined with photodynamic therapy and chemotherapy could significantly inhibit tumor growth and exert anti-tumor effect.Fig. 5Experimental study on antitumor in nude mice.(A) Curves of subcutaneous tumor volume with time after treatment in nude mice of each experimental group. (B) Appearance of excised subcutaneous tumors in nude mice:Group 1:PBS(control);Group 2:H-MnO2@IR825; Group 3: DTX; Group 4: H-MnO2@IR825/DTX; Group 5: PBS+laser (control); Group 6: H-MnO2@IR825+laser; Group 7:H-MnO2@IR825/DTX+laser.(C) Temperature curves of nude mouse surface tumors under laser irradiation.(D) Thermogram of nude mouse body surface recorded with a thermal infrared camera during laser irradiation.(E) Biological distribution of H-MnO2@IR825-DTX/DiR nanoparticles in nude mice. Experimental study on antitumor in nude mice.(A) Curves of subcutaneous tumor volume with time after treatment in nude mice of each experimental group. (B) Appearance of excised subcutaneous tumors in nude mice:Group 1:PBS(control);Group 2:H-MnO2@IR825; Group 3: DTX; Group 4: H-MnO2@IR825/DTX; Group 5: PBS+laser (control); Group 6: H-MnO2@IR825+laser; Group 7:H-MnO2@IR825/DTX+laser.(C) Temperature curves of nude mouse surface tumors under laser irradiation.(D) Thermogram of nude mouse body surface recorded with a thermal infrared camera during laser irradiation.(E) Biological distribution of H-MnO2@IR825-DTX/DiR nanoparticles in nude mice. Biodistribution of the H-MnO2@IR825/DTX nanoparticles The biodistribution and metabolic behavior of DiR in animals were monitored using an in vivo fluorescence imaging system (IVIS). Following tail vein injection of free DiR, the fluorescence signal was rapidly metabolized; no signal was detectable at the tumor site, and fluorescence was observed primarily in the bladder and subsequently excreted in the urine within 24 hours. In contrast, after tail vein injection of H-MnO2@IR825/DTX/DiR (10 mg kg-1), the fluorescence signal of DiR at the tumor site gradually increased over time, and significant nanoparticle accumulation in the tumor region was observed 12 hours post-injection (Fig. 5E). This tumor‑specific accumulation is attributed to the enhanced permeability and retention (EPR) effect of the nanoparticles. Compared with normal tissues, tumor tissues exhibit wider vascular wall gaps and compromised structural integrity, allowing nanoparticles of appropriate size and surface characteristics to preferentially extravasate and be retained. Thus, the nanodrug achieves passive accumulation in tumor tissues via the EPR effect without the need for an active targeting ligand. These results demonstrate that the constructed nanodrug exhibits favorable tumor-specific accumulation and can potentially release DTX locally to exert its antitumor effect. In vivo photothermal characteristics of the nanoparticles To study the photothermal effect of the nanoparticles in vivo, one nude mouse from each treatment group was selected for the experiment 24 hours after tail vein injection of the nanoparticles. After inhalation anesthesia, the nude mice were irradiated with 808nm laser for 10min at a power density of 2W/cm2. The tumor sites of these nude mice were monitored in real time by infrared thermography, and the temperature changes of the tumor sites were recorded in detail. The experimental results showed that under laser irradiation, the temperature of the nude mice in the PBS and DTX treatment groups did not increase significantly, while the temperature of the tumor site in the H-MnO2@IR825/DTX treatment group increased rapidly, with an average temperature increase of about 10℃(Fig. 5C and 5D). This significant photothermal effect indicates a high enrichment of nanoparticles inside the animal tumor. The H-MnO2@IR825/DTX nanoparticles with stable heating properties in animals, provided new ideas and methods for tumor diagnosis and treatment. Evaluation of apoptosis in vivo After 14 days, all BALB/c nude mice receiving different treatment modalities will be given inhaled anesthetic drugs and subsequently sacrificed to remove tumors. Cell apoptosis was detected by HE, TUNEL and PCNA staining. TUNEL fluorescence staining showed that the green fluorescence of tumor cells in the H-MnO2@IR825/DTX+laser group was the strongest, which confirmed that the combined treatment group had the best anti-tumor effect (Fig. 6A and 6B). At the same time, the tumor tissue was stained with PCNA, and the staining results showed that the tumor cell proliferation activity was the lowest in the H-MnO2@IR825/DTX+laser group, and the cell proliferation activity was the highest in the PBS treatment group (Fig. 6C). These results suggested that the H-MnO2@IR825/DTX nanoparticles in this study have an inhibitory effect on the proliferation of tumor tissues and exert anti-tumor effects through the mechanism of synergistic therapy.Fig. 6Representative images of stained tumor tissue sections of nude mice after treatment in each experimental group. (A) HE. (B) TUNEL. (C) PCNA. (D) ROS.(E) Hif-1ɑ. Representative images of stained tumor tissue sections of nude mice after treatment in each experimental group. (A) HE. (B) TUNEL. (C) PCNA. (D) ROS.(E) Hif-1ɑ. Evaluation of ROS and HIF-1ɑ production One nude mouse in each group was anesthetized by inhalation, and the tumor was removed after death. The tumor tissue was immediately preserved in liquid nitrogen, and the difference in ROS production in the tumor was detected by frozen section.The results showed that the tumor tissues in groups 6 and 7 produced the most ROS. H-MnO2@IR825/DTX had the characteristics of catalase, which not only catalyzed H2O2 to produce oxygen, but also produced a large amount of singlet oxygen under laser irradiation. ROS production was closely related to PDT treatment and PTT mediated temperature increase. The synergy promotes ROS production (Fig. 6D). HIF-1ɑ is ubiquitous in human cells, and the expression of HIF-1ɑ subunit is basically undetectable in cells under normal oxygen saturation. Under hypoxia, the degradation of HIF-1ɑ subunit is inhibited, and it is transferred to the nucleus to regulate the transcription of a variety of genes. The expression level of Hif-1ɑ is closely related to the invasiveness of tumors. The results of Hif-1ɑ immunohistochemical staining showed that the expression of Hif-1ɑ was significantly decreased in groups 6 and 7, while it was significantly increased in the PBS treatment group, which further proved that H-MnO2 could catalyze hydrogen peroxide to produce a large amount of oxygen, improve the hypoxic state of the tumor microenvironment, and enhance the effect of different treatment modes (Fig. 6E). The hypoxic characteristics of tumors are a key factor limiting PDT efficacy and promoting malignant progression. Our platform utilizes the catalase-like activity of H-MnO2, which specifically catalyzes the decomposition of overexpressed H2O2 in the TME into O2. This process ingeniously transforms the tumor’s “disadvantage” (high H2O2) into a therapeutic "advantage." The generated O2 not only directly alleviates tumor hypoxia and disrupts the stability of hypoxia-inducible factor HIF-1α (its expression is significantly downregulated in the combined treatment group, thereby inhibiting tumor invasiveness) but also provides sufficient “ammunition” for IR825-mediated PDT, significantly enhancing singlet oxygen production. Furthermore, the decomposition of H-MnO2 generates Mn2+ ions, which can deplete intracellular glutathione (GSH) and participate in Fenton-like reactions to produce hydroxyl radicals (•OH), achieving cascade amplification of ROS and sensitizing tumor cells to chemotherapy (Fig. 7)Fig. 7Representative images of stained tumor tissue sections of nude mice after treatment in each experimental group. (A) NLRP3. (B) Casp-1. (C) GSDMD. (D)IL-1β. Representative images of stained tumor tissue sections of nude mice after treatment in each experimental group. (A) NLRP3. (B) Casp-1. (C) GSDMD. (D)IL-1β. ). In vivo verification of pyroptosis pathway activation Our in vitro results demonstrated that H-MnO2@IR825/DTX combined with NIR irradiation promotes ROS-dependent pyroptosis via the NLRP3/Caspase-1/GSDMD signaling pathway. To further investigate the in vivo mechanism of tumor inhibition by the nanomedicine plus laser treatment, key regulatory proteins involved in pyroptosis, including NLRP3, Caspase-1, and the N-terminal fragment of Gasdermin D (GSDMD-N), were examined in tumor tissues of nude mice. Immunohistochemical (IHC) staining revealed that combination treatment with H-MnO2@IR825/DTX plus laser irradiation (Group 7) significantly upregulated the expression of these pyroptosis‑associated proteins(Fig.7), as evidenced by intense dark‑brown staining in tumor tissues, compared with the control groups (Groups 1 and 2). Western blot analysis further confirmed the elevated expression of NLRP3, cleaved Caspase-1, and GSDMD-N in the combination treatment group(Fig.8). Collectively, our in vivo findings are consistent with the in vitro results, demonstrating that H-MnO2@IR825/DTX combined with NIR irradiation promotes ROS-dependent pyroptosis through the NLRP3/Caspase-1/GSDMD signaling pathway, thereby contributing to the potent antitumor efficacy against prostate cancer .Fig. 8Detection of the expression of key proteins in the pyroptosis pathway in tumor tissues of nude mice by WB:Group 1: PBS(control); Group 2: DTX; Group 3:H-MnO2@IR825; Group 4: H-MnO2@IR825/DTX; Group 5: PBS+laser; Group 6: H-MnO2@IR825+laser; Group 7: H-MnO2@IR825/DTX+laser.All blots were not trimmed prior to antibody incubation; the band regions shown in the figure are from intact membranes, with trimming only removing areas without bands. The complete membrane images are shown in Supplementary Figure S12. Detection of the expression of key proteins in the pyroptosis pathway in tumor tissues of nude mice by WB:Group 1: PBS(control); Group 2: DTX; Group 3:H-MnO2@IR825; Group 4: H-MnO2@IR825/DTX; Group 5: PBS+laser; Group 6: H-MnO2@IR825+laser; Group 7: H-MnO2@IR825/DTX+laser.All blots were not trimmed prior to antibody incubation; the band regions shown in the figure are from intact membranes, with trimming only removing areas without bands. The complete membrane images are shown in Supplementary Figure S12. Biotoxicity testing of the nanoparticles in vivo H&E staining of major organs (heart, liver, spleen, lungs, kidneys) revealed no significant histological abnormalities or signs of toxicity across all treatment groups compared to controls (Fig. S13), indicating good biocompatibility of the nanoplatform. Conclusions In summary, we have developed an innovative H-MnO2@IR825/DTX nanoplatform that integrates tumor-targeted drug delivery with multimodal synergistic therapy and more importantly intelligent modulation of the tumor microenvironment (TME). This system achieves not only high docetaxel loading and pH-triggered release but also exhibits excellent photothermal stability and robust photodynamic performance. A key innovation of this platform lies in its TME-responsive therapeutic synergy. The catalase-like activity of H-MnO2 effectively alleviates tumor hypoxia by catalyzing the decomposition of overexpressed H2O2 into O2, thereby enhancing the efficacy of both photodynamic therapy (PDT) and chemodynamic therapy (CDT). Meanwhile, H-MnO2 decomposition depletes glutathione (GSH) and generates Mn2+ for CDT, further amplifying oxidative stress. Under near-infrared (NIR) irradiation, the nanoplatform simultaneously activates photothermal therapy (PTT), PDT, and CDT, which, together with the controlled release of docetaxel, results in a powerful cooperative antitumor effect, as validated by both in vitro and in vivo experiments. Mechanistically, the multimodal treatment alleviates hypoxia (downregulating HIF-1α). More importantly, our study reveals that the ROS burst induced by the nanoplatform triggers pyroptosis via the NLRP3/Caspase-1/GSDMD signaling pathway, both in vitro and in vivo. This pro-inflammatory form of programmed cell death further amplifies the antitumor immune response and contributes significantly to the overall therapeutic efficacy. It is important to acknowledge that the present study is entirely preclinical, conducted using subcutaneous xenograft models in immunodeficient mice. While the H-MnO2@IR825/DTX nanoplatform demonstrated potent antitumor efficacy and a favorable safety profile in these animal models, the results cannot be directly extrapolated to human patients. Future clinical trials will be essential to validate the safety, tolerability, and therapeutic efficacy of this nanoplatform in prostate cancer patients.In addition to the need for clinical validation, the clinical translation of the H-MnO2@IR825/DTX nanoplatform faces challenges related to scalability and Good Manufacturing Practice (GMP) compliance. Therefore, future work should focus on developing scalable manufacturing processes, potentially including continuous flow synthesis or one-pot methods, while establishing robust quality control criteria for particle size, polydispersity, drug loading, and sterility. Achieving GMP-grade production will be a critical step toward regulatory approval and eventual clinical application. These considerations provide a realistic perspective on the path from bench to bedside. Collectively, this rationally designed nanoplatform represents a promising and translatable strategy for effective and low-toxicity treatment of advanced prostate cancer, with its multifaceted mechanisms involving apoptosis, proliferation suppression, hypoxia relief, and ROS-dependent pyroptosis. Supplementary Information Supplementary Information 1. Supplementary Information 2. Supplementary Information 3. Supplementary Information 1. Supplementary Information 2. Supplementary Information 3.